目的:评价气管镜下介入联合瘤体药物注射方法对于中央型非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性和安全性.方法:符合试验入排标准的64名患者,对纳入试验的患者按照1∶1的比例随机分配试验组和对照组,分别给予支气管镜下介入及局部注射顺铂、重组人血管内皮抑素联合含铂双药化疗与单纯含铂双药化疗,比较两组的疗效以及安全性.结果:与对照组相比,试验组患者 Karnofsky 功能状态(karnofsky performance status,KPS)评分、气促分级均得到明显改善(P<0.05).试验组的治疗总有效率为78.12%,对照组的总有效率为37.5%,两组间比较差异具有统计学意义(P<0.05),两组生存情况比较差异有统计学意义(P<0.05).结论:经支气管镜介入联合药物注射治疗中央型NSCLC临床疗效显著,能有效改善临床症状,提高患者生存质量.两组患者不良反应比较,无显著差异,值得推广应用.
AIM:To evaluate the efficacy and safe-ty of interventional therapy combined with tumor drug injection under bronchoscope for central non-small cell lung cancer(NSCLC).METHODS:Sixty-four patients who met the test admission criteria were randomly assigned to the experimental group and the control group according to the ratio of 1:1,and were given bronchoscopic interventional thera-py combined with local drug injection of recombi-nant human endostatin combined with platinum-containing dual-drug chemotherapy and platinum-containing dual-drug alone,respectively.The cura-tive efficiency and safety of the two groups were compared.RESULTS:Compared with the control group,the KPS score,dyspnea grading were signifi-cantly improved(P<0.05).The effective rate of the test group was 78.12%,which was higher than 37.5%in the control group,the difference between the two groups was significant(P<0.05).Moreover,there was also a significant difference in the 1-year survival rate between the experimental group and the control group(P<0.05).CONCLUSION:The treatment of central NSCLC by interventional thera-py combined with tumor drug injection through fi-beroptic bronchoscope has obvious clinical efficacy,which can effectively alleviate the clinical symp-toms and improve the quality of life of patients.There is no significant difference in adverse reac-tions between the two groups,and is worthy of popularization and application.